S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
S&P 500   4,591.67
DOW   35,227.03
QQQ   386.20
NYSE:IKT

Inhibikase Therapeutics Insider Trades

$1.55
-0.10 (-6.06%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.54
$1.63
50-Day Range
$1.55
$2.17
52-Week Range
$1.54
$11.80
Volume
302,336 shs
Average Volume
360,679 shs
Market Capitalization
$38.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Inhibikase Therapeutics (NYSE:IKT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
55.80%

Number Of
Insiders Buying
(Last 12 Months)
1

Amount Of
Insider Buying
(Last 12 Months)
$46.47 K

Number Of
Insiders Selling
(Last 12 Months)
0

Skip Chart & View Insider Trade History

Insider Buying and Selling by Quarter

Get IKT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Inhibikase Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.


Inhibikase Therapeutics (NYSE IKT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2021Milton H WernerCEOBuy23,589$1.97$46,470.33  
(Data available from 1/1/2013 forward)












Inhibikase Therapeutics (NYSE:IKT) Insider Trade Frequently Asked Questions

Who is on Inhibikase Therapeutics's Insider Roster?

The list of insiders at Inhibikase Therapeutics includes Milton H Werner.Learn more on IKT's insiders

What percentage of Inhibikase Therapeutics stock is owned by insiders?

55.80% of Inhibikase Therapeutics stock is owned by insiders. Learn more on IKT's insider holdings

Which Inhibikase Therapeutics insiders have been buying company stock?

The following insider purchased Inhibikase Therapeutics stock in the last 24 months: Milton H Werner ($46,470.33).

How much insider buying is happening at Inhibikase Therapeutics?

Insiders have purchased a total of 23,589 Inhibikase Therapeutics shares in the last 24 months for a total of $46,470.33 bought.

This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.